Indicated for: non-small cell lung cancer; pancreatic cancer
Route of administration: oral
Substance: erlotinib (tyrosine kinase inhibitor)
ATC: L01EB02 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors)
Erlotinib is a medication used in the treatment of certain types of lung cancer and advanced pancreatic cancer. It works by blocking a protein involved in the growth and multiplication of cancer cells, thus helping to slow disease progression.
Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.
Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.
Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.